中科通达(688038) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥35,233,856.15, a decrease of 52.94% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2023 was -¥12,131,633.64, with a year-to-date net profit of -¥19,244,548.74, reflecting a significant decline of 560.73% year-on-year[6]. - Total revenue for the first three quarters of 2023 was CNY 158,952,460.51, a decrease of 26.2% compared to CNY 215,333,813.61 in the same period of 2022[22]. - Net profit for the first three quarters of 2023 was a loss of CNY 19,244,548.74, compared to a profit of CNY 4,176,937.20 in the same period of 2022[23]. - The total comprehensive income attributable to the parent company was -CNY 19,244,548.74, a decline from CNY 4,176,937.20 in the previous year[24]. Cash Flow - The cash flow from operating activities for Q3 2023 was -¥58,093,954.64, indicating a substantial decrease in cash inflow compared to the previous year[7]. - The company's cash inflow from operating activities for the first three quarters of 2023 was CNY 194,397,780.44, an increase of 9.3% compared to CNY 177,174,789.28 in the same period of 2022[26]. - The net cash flow from operating activities was -CNY 100,665,822.31, an improvement from -CNY 115,311,150.68 in the first three quarters of 2022[26]. - The cash inflow from investment activities was CNY 347,492,974.98, down from CNY 524,414,212.80 in the previous year[27]. - The total cash and cash equivalents at the end of the period was CNY 59,427,718.92, down from CNY 72,203,321.17 at the end of the same period in 2022[27]. Research and Development - Research and development expenses totaled ¥8,105,804.99 in Q3 2023, accounting for 23.01% of operating revenue, an increase of 10.03 percentage points year-on-year[7]. - Research and development expenses for the first three quarters of 2023 were CNY 22,343,885.00, a decrease of 9.2% from CNY 24,619,172.00 in the same period of 2022[22]. - The company is focusing on long-term sustainable development by increasing investments in R&D and expanding its market presence despite current financial challenges[12]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,318,521,293.04, showing a slight increase of 0.54% from the end of the previous year[7]. - The total liabilities of the company as of September 30, 2023, amounted to CNY 616,733,896.92, an increase from CNY 590,461,828.30 at the end of 2022[21]. - The total equity attributable to shareholders as of September 30, 2023, was CNY 701,787,396.12, down from CNY 721,031,944.86 at the end of 2022, representing a decrease of 2.9%[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,369[14]. - The largest shareholder, Wang Kaixue, holds 18,971,880 shares, representing 16.30% of total shares[14]. Other Financial Metrics - The basic earnings per share for Q3 2023 was -¥0.10, with a year-to-date figure of -¥0.17, reflecting a decrease of 525.00%[7]. - The company reported a significant decline in gross margin due to increased market competition and macroeconomic factors, impacting overall revenue and profitability[12]. - The company incurred interest expenses of CNY 10,689,101.53 in the first three quarters of 2023, up from CNY 6,470,840.13 in the same period of 2022, indicating a rise of 65.5%[22]. - The company reported a decrease in other income, which fell to CNY 1,878,365.91 in the first three quarters of 2023 from CNY 7,898,594.79 in the same period of 2022, a decline of 76.2%[22].